Non-Hospitalized 1 Ulcerative Colitis : The Toronto Consensus 2 3

Brian Bressler, John K. Marshall, Charles N. Bernstein, Alain Bitton, Jennifer Jones, Grigorios I. Leontiadis, Remo Panaccione, A. Hillary Steinhart, Francis Tse, Brian Feagan, on behalf of the Toronto Ulcerative Colitis Consensus Group, Waqqas Afif, Edmond-Jean Bernard, Mark Borgaonkar, Shane Devlin, Richard Fedorak, Geoffrey C. Nguyen, Robert Penner, Laurent Peyrin-Biroulet, Walter Reinisch, Cynthia H. Seow, Richmond Sy, Laura Targownik, Peter Thomson, Gert Van Assche, Chadwick Williams

[1]  B. Feagan,et al.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[2]  M. Nurmohamed,et al.  Key findings towards optimising adalimumab treatment: the concentration-effect curve. , 2015, Annals of the rheumatic diseases.

[3]  A. Petersen,et al.  Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. , 2014, Journal of Crohn's & colitis.

[4]  A. Grigorian,et al.  Probiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative Colitis: A Meta-analysis , 2014, Inflammatory bowel diseases.

[5]  L. Peyrin-Biroulet,et al.  Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases , 2014, The American Journal of Gastroenterology.

[6]  C. Bernstein,et al.  Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease. , 2014, Canadian journal of gastroenterology & hepatology.

[7]  L. Kupčinskas,et al.  First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses , 2014, The American Journal of Gastroenterology.

[8]  J. Lewis,et al.  Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. , 2014, Gastroenterology.

[9]  J. Ariyaratnam,et al.  Association Between Thiopurine Use and Nonmelanoma Skin Cancers in Patients With Inflammatory Bowel Disease: A Meta-Analysis , 2014, The American Journal of Gastroenterology.

[10]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[11]  Zhixiang Zuo,et al.  Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohn's Disease, and Pouchitis: Meta-analysis of Randomized Controlled Trials , 2014, Inflammatory bowel diseases.

[12]  R. Hunt,et al.  Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. , 2014, Canadian journal of gastroenterology & hepatology.

[13]  P. Rutgeerts,et al.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[14]  L. Peyrin-Biroulet,et al.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  P. Rutgeerts,et al.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[16]  J. Macdonald,et al.  Methotrexate for induction of remission in ulcerative colitis. , 2014, The Cochrane database of systematic reviews.

[17]  C. Bernstein,et al.  Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD , 2013, The American Journal of Gastroenterology.

[18]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[19]  B. Feagan,et al.  Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews , 2013, Inflammatory bowel diseases.

[20]  W. Sandborn,et al.  52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants , 2013, Inflammatory bowel diseases.

[21]  N. Khan,et al.  Methotrexate in Ulcerative Colitis: A Nationwide Retrospective Cohort from the Veterans Affairs Health Care System , 2013, Inflammatory bowel diseases.

[22]  P. Rutgeerts,et al.  Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient , 2013, The American Journal of Gastroenterology.

[23]  B. Flourié,et al.  Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience , 2013, Alimentary pharmacology & therapeutics.

[24]  S. Travis,et al.  Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study , 2013, Gut.

[25]  A. Schoepfer,et al.  Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes , 2013, Inflammatory bowel diseases.

[26]  G. D'Haens,et al.  One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2 , 2013, Alimentary pharmacology & therapeutics.

[27]  S. Vermeire,et al.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. , 2012, Journal of Crohn's & colitis.

[28]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[29]  M. Thabane,et al.  Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2012, The Cochrane database of systematic reviews.

[30]  A. Bitton,et al.  Inflammatory bowel disease: a Canadian burden of illness review. , 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[31]  R. Bagin,et al.  Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. , 2012, Gastroenterology.

[32]  B. Feagan,et al.  Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta‐analysis , 2012, Inflammatory bowel diseases.

[33]  Michael D. Kappelman,et al.  Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population , 2012, Digestive Diseases and Sciences.

[34]  W. Sandborn,et al.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.

[35]  W. Sandborn,et al.  Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry , 2012, The American Journal of Gastroenterology.

[36]  D. Mould,et al.  Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose‐ranging Study , 2012, Inflammatory bowel diseases.

[37]  T. Matsui,et al.  Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohn's Disease , 2012, Inflammatory bowel diseases.

[38]  P. Moayyedi,et al.  Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  P. Rutgeerts,et al.  Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies , 2012, Inflammatory bowel diseases.

[40]  P. Moayyedi,et al.  Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2012, The American Journal of Gastroenterology.

[41]  A. Griffiths,et al.  Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements , 2012, The American Journal of Gastroenterology.

[42]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[43]  A. Timmer,et al.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2012, The Cochrane database of systematic reviews.

[44]  B. Warner,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[45]  S. Kane.  Strategies to Improve Adherence and Outcomes in Patients with Ulcerative Colitis , 2012, Drugs.

[46]  B. Feagan,et al.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2012, The Cochrane database of systematic reviews.

[47]  P. Moayyedi,et al.  Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[48]  M. Chaparro,et al.  Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. , 2011, Journal of Crohn's & colitis.

[49]  P. Rutgeerts,et al.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.

[50]  G. Porro,et al.  Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  P. Moayyedi,et al.  Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[52]  P. Moayyedi,et al.  Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[53]  L. Kupčinskas,et al.  3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. , 2011, Journal of Crohn's & colitis.

[54]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[55]  S. Schreiber,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[56]  W. Lems,et al.  The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review , 2010, Arthritis Research & Therapy.

[57]  A. Gelber.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[58]  J. Stein,et al.  Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left‐sided ulcerative colitis , 2010, Alimentary pharmacology & therapeutics.

[59]  F. Nagy,et al.  Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. , 2010, Journal of Crohn's & colitis.

[60]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[61]  J. Sanderson,et al.  Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease , 2010, Alimentary pharmacology & therapeutics.

[62]  J. Korzenik,et al.  Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. , 2010, Gastroenterology.

[63]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[64]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[65]  M. Thabane,et al.  Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.

[66]  F. Autschbach,et al.  Delayed Release Phosphatidylcholine in Chronic-active Ulcerative Colitis: A Randomized, Double-blinded, Dose Finding Study , 2009, Journal of clinical gastroenterology.

[67]  A. Griffiths,et al.  Oral budesonide for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.

[68]  J. Reguła,et al.  Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. , 2009, Gastroenterology.

[69]  W. Sandborn,et al.  Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials , 2009, Alimentary pharmacology & therapeutics.

[70]  T. Stijnen,et al.  Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[71]  J. Mate,et al.  Meta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis , 2009, Alimentary pharmacology & therapeutics.

[72]  K. Kaulback,et al.  Systematic review: impact of non‐adherence to 5‐aminosalicylic acid products on the frequency and cost of ulcerative colitis flares , 2009, Alimentary pharmacology & therapeutics.

[73]  M. Kamm,et al.  Effect of extended MMX mesalamine therapy for acute, mild‐to‐moderate Ulcerative Colitis , 2009, Inflammatory bowel diseases.

[74]  M. Vatn,et al.  Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) , 2009, Scandinavian journal of gastroenterology.

[75]  Dawn B. Beaulieu,et al.  History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis , 2008, Inflammatory bowel diseases.

[76]  M. Picco.  Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2009 .

[77]  M. Picco.  Mesalamine Foam Enema Versus Mesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis , 2009 .

[78]  A. Griffiths,et al.  Methotrexate for maintenance of remission in ulcerative colitis. , 2009, The Cochrane database of systematic reviews.

[79]  C. Porter,et al.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. , 2008, Gastroenterology.

[80]  G. Guyatt,et al.  Going from evidence to recommendations , 2008, BMJ : British Medical Journal.

[81]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[82]  G. Lichtenstein.  Phosphatidylcholine for Steroid-Refractory Chronic Ulcerative Colitis: A Randomized Trial , 2008 .

[83]  A. Lavy,et al.  Clinical trial: randomized‐controlled clinical study comparing the efficacy and safety of a low‐volume vs. a high‐volume mesalazine foam in active distal ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[84]  M. Vatn,et al.  Ulcerative Colitis: Patient Characteristics May Predict 10-Yr Disease Recurrence in a European-Wide Population-Based Cohort , 2007, The American Journal of Gastroenterology.

[85]  F. Manguso,et al.  Meta‐analysis: the efficacy of rectal beclomethasone dipropionate vs. 5‐aminosalicylic acid in mild to moderate distal ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[86]  J. Mate,et al.  5‐Aminosalicylates and renal function in inflammatory bowel disease: A systematic review , 2007, Inflammatory bowel diseases.

[87]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[88]  A. Griffiths,et al.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[89]  S. Hanauer,et al.  Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[90]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[91]  A. Akobeng.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Journal of pediatric gastroenterology and nutrition.

[92]  G. Lichtenstein.  Trichuris suis Therapy for Active Ulcerative Colitis: A Randomized Controlled Trial , 2006 .

[93]  F. Ajayi,et al.  Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial , 2005, The American Journal of Gastroenterology.

[94]  G. Porro,et al.  A rare cause of diuretic refractory ascites , 2005, Gut.

[95]  D. Bjorkman,et al.  Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. , 2004, Alimentary pharmacology & therapeutics.

[96]  G. Porro,et al.  Budesonide Foam vs. Hydrocortisone Acetate Foam in the Treatment of Active Ulcerative Proctosigmoiditis , 2003, Diseases of the colon and rectum.

[97]  F. Manguso,et al.  Oral beclometasone dipropionate in the treatment of extensive and left‐sided active ulcerative colitis: a multicentre randomised study , 2003, Alimentary pharmacology & therapeutics.

[98]  S. Hanauer,et al.  Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. , 2003, The American journal of medicine.

[99]  A. Cross,et al.  Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.

[100]  A. Sood,et al.  The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis , 2002, Journal of Gastroenterology.

[101]  S. Hanauer,et al.  Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis , 2001, American Journal of Gastroenterology.

[102]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[103]  L. Mortelmans,et al.  Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. , 2001, Gastroenterology.

[104]  R. Moreno-otero,et al.  6‐Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease , 2000, European journal of gastroenterology & hepatology.

[105]  J. Marshall,et al.  Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis , 2000, American Journal of Gastroenterology.

[106]  R. Thisted,et al.  A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis , 2000, American Journal of Gastroenterology.

[107]  A. Sood,et al.  Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. , 2000, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[108]  Pike,et al.  A randomized dose–response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn’s disease and ulcerative colitis , 1999, Alimentary pharmacology & therapeutics.

[109]  P. Gionchetti,et al.  Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis , 1998, Diseases of the colon and rectum.

[110]  S. Targan,et al.  A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. , 1997, The American journal of gastroenterology.

[111]  D. Cook,et al.  The Relation between Systematic Reviews and Practice Guidelines , 1997, Annals of Internal Medicine.

[112]  I. Wilding,et al.  Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy , 1997, Alimentary pharmacology & therapeutics.

[113]  I. Forgacs,et al.  Reduced bone density in patients with inflammatory bowel disease. , 1997, Gut.

[114]  A. V. van Bodegraven,et al.  Distribution of mesalazine enemas in active and quiescent ulcerative colitis. , 1996, Alimentary pharmacology & therapeutics.

[115]  Å. Danielsson,et al.  Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. , 1996, Gastroenterology.

[116]  O. Nielsen,et al.  Changes in extent of ulcerative colitis: a study on the course and prognostic factors. , 1996, Scandinavian journal of gastroenterology.

[117]  D. Jewell,et al.  A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. , 1996, Gut.

[118]  G. Porro,et al.  Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. , 1995, Journal of clinical gastroenterology.

[119]  R. Modigliani,et al.  Comparison of budesonide and 5‐aminosalicylic acid enemas in active distal ulcerative colitis , 1995, Alimentary pharmacology & therapeutics.

[120]  J. Marshall,et al.  Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysis , 1995, Alimentary pharmacology & therapeutics.

[121]  Ø. Hovde,et al.  Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. , 1995, Scandinavian journal of gastroenterology.

[122]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[123]  A. Axon,et al.  Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. , 1992, BMJ.

[124]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[125]  J. Lennard-jones,et al.  A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. , 1981, Digestion.

[126]  D. Jewell,et al.  Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic Trial , 1974, British medical journal.

[127]  Norman Crolee Dalkey,et al.  An experimental study of group opinion , 1969 .

[128]  J. H. Baron,et al.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION. , 1965, Lancet.

[129]  S. Truelove,et al.  Cortisone and Corticotrophin in Ulcerative Colitis , 1959, British medical journal.